Project chronology & history

Tafalgie Therapeutics came into being in October 2020.

This company brings together researchers and entrepreneurs with the shared aim of valorizing more than 10 years of fundamental research conducted by Dr. Aziz Moqrich and his team.

This work has been the subject of numerous publications and an international patent has been filed (by the SATT on behalf of the CNRS and AMU) concerning the use of a new protein as a potential analgesic for treating inflammatory and neuropathic pain.

There were a number of key stages in this project, extending from research to development :

1939:
Discovery of the type C low-threshold mechanoreceptor neuron class (C-LTMR) by Yngve Zotterman

2007:
Identification of the TAFA4 protein as a specific molecular marker of C-LTMR sensory neurons

2010:
Elucidation, by the team of Aziz Moqrich, of the role of the TAFA4 protein in pain gate control

2013:
Filing of a first patent linked to TAFA4 by Aziz Moqrich

2021/2022:
Filing of two new product patents in December 2021 and May 2022 (for polypeptide derived from TAFA4) by Tafalgie Therapeutics and the CNRS

Others key stages

2005-2006

Creation of 'Chronic Pain'

Creation of the team 'Chronic Pain' :

Molecular and cellular mechanisms” team by Dr. Aziz Moqrich from the IBDM, and Dr. Stephane Gaillard, who joined this new team

2020

Sublicense exploitation agreement

Sub-licence exploitation agreement

with Satt Sud-Est (SEE)

What is the SATT SUD-EST ?

2019-2020

Creation of Tafalgie Therapeutics

Creation of the company :

Completion of the Tafalgie Therapeutics founders by the arrival of Laurent Labatut and the establishment of a support team

2022

The company begins operating, with the performance of preclinical studies...

The company begins operating, with the performance of preclinical studies

R&D activities, regulatory activities, the establishment of a scientific advisory board and efforts to obtain financial support

Contact us
for more information

JOIN US

Click here